|
|
Blood, 15 June 2007, Vol. 109, No. 12, pp. 5160-5163.
Prepublished online as a Blood First Edition Paper on March 5, 2007; DOI 10.1182/blood-2006-12-063594.
 Previous Article | Next Article 
Submitted December 19, 2006
Accepted February 26, 2007
A novel proteoliposomal vaccine induces antitumor
immunity against follicular lymphoma
Sattva S. Neelapu*, Barry L Gause, Linda Harvey, Seung-Tae Lee, Andrea Robin Frye, Jessie Horton, Richard J Robb, Mircea C Popescu, and Larry W Kwak
Experimental and Transplantation Immunology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, United States
SAIC, NCI at Frederick, Frederick, MD, United States
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Biomira USA Inc., Cranbury, NJ, United States
XEME Biopharma Inc., Plainsboro, NJ, United States
* Corresponding author; email: sneelapu{at}mdanderson.org.
Clinical studies suggest that treatment with vaccines comprised of idiotype protein may be associated with improved clinical outcome in follicular lymphoma patients. However, the time-consuming process required to generate patient-specific vaccines is a major limitation. Here, we report results of a pilot clinical trial with a novel autologous, tumor-derived proteoliposome vaccine formulation that could be rapidly produced within a single day. Vaccination was safe, induced autologous tumor-specific type 1 cytokine responses in 5 out of 10 follicular lymphoma patients, and was associated with induction of a sustained complete response in one patient. Other patients had large tumor burdens and progressed after a median duration of 8 months. These results suggest that further testing of this vaccine formulation, particularly in the setting of minimal disease is warranted. Furthermore, the proteoliposome formulation may provide a model for vaccine development for other human cancers, for which tumor-associated antigens need not be defined.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Foglietta, S. S. Neelapu, and L. W. Kwak
Therapeutic Vaccines for Lymphoma: From Bench to Bedside
ASCO Educational Book,
January 1, 2009;
2009(1):
495 - 500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Di Nicola, R. Zappasodi, C. Carlo-Stella, R. Mortarini, S. M. Pupa, M. Magni, L. Devizzi, P. Matteucci, P. Baldassari, F. Ravagnani, et al.
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
Blood,
January 1, 2009;
113(1):
18 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Houot and R. Levy
Therapeutic Vaccine for Lymphoma: Lessons Learned and Future Directions
Am. Assoc. Cancer Res. Educ. Book,
April 12, 2008;
2008(1):
3 - 11.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Neelapu and L. W. Kwak
Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies
Hematology,
January 1, 2007;
2007(1):
243 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
